SEATTLE–(BUSINESS WIRE)– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy
company focused on the development of treatments for
autoimmune/inflammatory diseases and cancer, announced today that the
company will present at the Ladenburg Thalmann 2017 Healthcare
Conference in New York on Tuesday, September 26, 2017, at 10:00am
Eastern Time.
A live webcast of the presentation will be available online from the
investors relations page of the company’s website at https://ir.alpineimmunesciences.com/events.
After the webcast, an archive of the presentation will be available on
the company website for 90 days.
About Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.
is focused on developing novel protein-based immunotherapies using its
proprietary Variant Ig Domain™ vIgD™ platform technology. The vIgD
platform is designed to interact with multiple targets, including many
present in the immune synapse. Alpine’s vIgDs are developed using a
process known as directed evolution, which produces proteins capable of
either enhancing or diminishing an immune response and thereby may
potentially apply therapeutically to cancer, autoimmune, and
inflammatory diseases. Alpine has also developed TIP™ technology, based
on the vIgD platform, to potentially enhance engineered cellular
therapies. In October 2015, Alpine signed a worldwide research and
license agreement with Kite Pharma, Inc. (NASDAQ:KITE) for up to $535
million in up front and potential milestone payments plus royalties on
resulting sales. For more information visit www.alpineimmunesciences.com/.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170913006360/en/
Contacts
For Alpine Immune Sciences, Inc.
Investors:
Courtney
Dugan, 212-257-6723
cdugan@purecommunications.com
Source: Alpine Immune Sciences, Inc.
Cet article Alpine Immune Sciences to Present at Ladenburg Thalmann 2017
Healthcare Conference est apparu en premier sur EEI-BIOTECHFINANCES.